Resumen de acción MARKSANS
Marksans Pharma Limited, junto con sus filiales, se dedica a la investigación y desarrollo, fabricación, comercialización y venta de formulaciones farmacéuticas genéricas en todo el mundo.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Recompensas
Análisis de riesgos
Competidores de Marksans Pharma Limited
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | ₹169.15 |
| 52 Week High | ₹185.50 |
| 52 Week Low | ₹70.55 |
| Beta | 1.6 |
| 1 Month Change | 11.36% |
| 3 Month Change | 15.07% |
| 1 Year Change | 109.34% |
| 3 Year Change | 126.44% |
| 5 Year Change | 635.43% |
| Change since IPO | -37.80% |
Noticias y actualizaciones recientes
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
Feb 16
Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
Jan 26We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02Recent updates
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
Feb 16Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
Jan 26We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Jun 21Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Nov 17This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation
Sep 16Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25
Sep 01Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt
Jun 14Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
May 27Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?
Feb 19Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 04Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching
Jan 20Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?
Jan 05
Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%
Dec 21What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?
Dec 06These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely
Nov 19Marksans Pharma Limited's (NSE:MARKSANS) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Nov 04If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late
Oct 20Is Marksans Pharma Limited's (NSE:MARKSANS) Shareholder Ownership Skewed Towards Insiders?
Oct 05If You Had Bought Marksans Pharma (NSE:MARKSANS) Shares A Year Ago You'd Have Earned273% Returns
Sep 20A Look At The Fair Value Of Marksans Pharma Limited (NSE:MARKSANS)
Aug 20Many Still Looking Away From Marksans Pharma Limited (NSE:MARKSANS)
Aug 05If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late
Jul 08Rentabilidad de los accionistas
| MARKSANS | IN Pharmaceuticals | Mercado IN | |
|---|---|---|---|
| 7D | 0.7% | 1.6% | 2.1% |
| 1Y | 109.3% | 57.6% | 45.9% |
Rentabilidad vs. Industria: MARKSANS superó al sector Indian Pharmaceuticals , que obtuvo un rendimiento del 56.7% el año pasado.
Rentabilidad vs. Mercado: MARKSANS superó al mercado Indian, que obtuvo un rendimiento del 46.4% el año pasado.
Volatilidad de los precios
| MARKSANS volatility | |
|---|---|
| MARKSANS Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.0% |
| 10% least volatile stocks in IN Market | 4.2% |
Precio estable de las acciones: MARKSANS no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de MARKSANS (7%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1992 | 852 | Mark Saldanha | marksanspharma.com |
Marksans Pharma Limited, junto con sus filiales, se dedica a la investigación y desarrollo, fabricación, comercialización y venta de formulaciones farmacéuticas genéricas en todo el mundo. La empresa ofrece productos en las áreas terapéuticas de analgésicos, hiperplasia prostática benigna, antidiabéticos, epilepsia, antiinflamatorios, hiperparatiroidismo, diabetes, antiácidos, neurología, cardiovascular, hormonal, oncología, gastroenterología, antidiabéticos, tratamiento del dolor, ginecología, antifúngicos, antiulcerosos, vitaminas, dermatología, cefalosporinas, inyectables, antialérgicos, antibacterianos e hipertensión. Marksans Pharma Limited se constituyó en 1992 y tiene su sede en Bombay (India).
Resumen de fundamentos de Marksans Pharma Limited
| Estadísticas fundamentales de MARKSANS | |
|---|---|
| Capitalización bursátil | ₹76.65b |
| Beneficios(TTM) | ₹3.16b |
| Ingresos (TTM) | ₹21.03b |
24.2x
Ratio precio-beneficio (PE)3.6x
Ratio precio-ventas (PS)¿Está MARKSANS sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de MARKSANS | |
|---|---|
| Ingresos | ₹21.03b |
| Coste de los ingresos | ₹10.31b |
| Beneficio bruto | ₹10.72b |
| Otros gastos | ₹7.56b |
| Beneficios | ₹3.16b |
Últimos beneficios comunicados
Dec 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 6.98 |
| Margen bruto | 50.99% |
| Margen de beneficio neto | 15.04% |
| Ratio deuda/patrimonio | 5.9% |
¿Cómo se ha desempeñado MARKSANS a largo plazo?
Ver rendimiento histórico y comparativa